Skip to main content

Advertisement

SpringerLink
Log in

New antirheumatic drugs: any real added value? A critical overview of regulatory criteria for their marketing approval

  • Point of View
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective

Rheumatoid arthritis (RA) is a systemic autoimmune disorder causing chronic polyarticular synovial inflammation and progressive joint damage. New anti-rheumatic drugs, such as leflunomide, infliximab, etanercept, adalimumab and anakinra, have recently become available. The aim of this paper is to summarize and critically evaluate the type of studies and clinical endpoints accepted by the European Medicines Agency (EMEA) to approve these new drugs.

Materials and methods

Information regarding the approval of antirheumatic drugs was obtained from European Public Assessment Reports (EPARs) and published pivotal studies.

Results

Leflunomide is the only non-biological disease-modifying anti-rheumatic drug (DMARD) to receive recent approval for RA treatment, but strong evidence of its superiority over conventional therapies is lacking. Anakinra in combination with methotrexate received approval as a DMARD for RA on the basis of two pivotal trials in which American College of Rheumatology response criteria (ACR 20 response) were used as the sole primary endpoint. For easier demonstration of efficacy, studies leading to first approval of etanercept, infliximab and adalimumab were carried out on non-responders to DMARDs. Once on the market, these drugs gained an extension of the indication to methotrexate-naïve patients. Studies that provided the basis for approval were not adequately designed, given the lack of an active control and the choice of ACR response as the only clinical endpoint. Consequently, only a weak proof of efficacy emerged for the treatment of signs and symptoms of RA, and these drugs failed to show real benefit in slowing radiographic progression. Serious infections, changes in blood cell counts, severe skin and hepatic infections were the main adverse events that emerged from the clinical studies. Therefore, the unconvincing benefit of the new antirheumatic drugs can scarcely outweigh the risk associated with their use. Moreover, the monthly costs in Italy of the new biological preparations are several fold higher than those of the reference drugs.

Conclusions

Recently approved anti-RA products should be a therapeutic option only for patients refractory to conventional drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Furst DE (2004) Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis. Clin Ther 26(12):1960–1975

    Article  PubMed  CAS  Google Scholar 

  2. Moore RA, Derry S, Makinson GT, McQuay HJ (2005) Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther 7(3):R644–R665

    Article  PubMed  CAS  Google Scholar 

  3. Mobley JL (2006) Using epidemiology and archaeology to unearth new drug targets for rheumatoid arthritis therapy. Drug Discov Today 11(1–2):4–7

    Article  PubMed  CAS  Google Scholar 

  4. Alamanos Y, Drosos AA (2005) Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 4(3):130–136

    Article  PubMed  Google Scholar 

  5. Sarzi-Puttini P, Atzeni F, Shoenfeld Y, Ferraccioli G (2005) TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma. Autoimmun Rev 4(3):153–161

    Article  PubMed  CAS  Google Scholar 

  6. Lewis C (2000) Arthritis. Timely treatments for an ageless disease. FDA Consum 34(3):27–29, 31–33.

    PubMed  CAS  Google Scholar 

  7. Konttinen YT, Seitsalo S, Lehto M, Santavirta S (2005) Current management: Management of rheumatic diseases in the era of biological anti-rheumatic drugs. Acta Orthop 76(5):614–619

    Article  PubMed  Google Scholar 

  8. Weaver AL (2004) The impact of new biologicals in the treatment of rheumatoid arthritis. Rheumatology 43[Suppl 3]:iii17–iii23

    Article  PubMed  Google Scholar 

  9. Afeltra A (2001) Treatment of rheumatoid arthritis: new therapeutic approaches with biological agents. Curr Drug Targets Immune Endocr Metabol Disord 1(1):45–65

    Article  PubMed  CAS  Google Scholar 

  10. Genovese MC (2005) Biologic therapies in clinical development for the treatment of rheumatoid arthritis. J Clin Rheumatol 11[Suppl 3]:S45–S54

    Article  PubMed  Google Scholar 

  11. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A et al (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 353(9149):259–266

    Article  PubMed  CAS  Google Scholar 

  12. http://www.emea.europa.eu/humandocs/Humans/EPAR/arava/arava.htm.

  13. Scott DL, Smolen JS, Kalden JR, van de Putte LB, Larsen A, Kvien TK et al (2001) Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 60(10):913–923

    Article  PubMed  CAS  Google Scholar 

  14. Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gomor B et al (2000) A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 39(6):655–665

    Article  CAS  Google Scholar 

  15. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G et al (1999) Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 159(21):2542–2550

    Article  PubMed  CAS  Google Scholar 

  16. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M et al (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354(9194):1932–1939

    Article  PubMed  CAS  Google Scholar 

  17. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343(22):1594–1602

    Article  PubMed  CAS  Google Scholar 

  18. http://www.emea.europa.eu/humandocs/Humans/EPAR/remicade/remicade.htm.

  19. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P et al (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50(11):3432–3443

    Article  PubMed  CAS  Google Scholar 

  20. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ et al (1999) Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130(6):478–486

    PubMed  CAS  Google Scholar 

  21. http://www.emea.europa.eu/humandocs/Humans/EPAR/enbrel/enbrel.htm.

  22. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340(4):253–259

    Article  PubMed  CAS  Google Scholar 

  23. Jobanputra P, Barton P, Bryan S, Burls A (2002) The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 6(21):1–110

    PubMed  CAS  Google Scholar 

  24. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH et al (2002) Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 46(6):1443–1450

    Article  PubMed  CAS  Google Scholar 

  25. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M et al (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363(9410):675–681

    Article  PubMed  CAS  Google Scholar 

  26. Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T et al (2004) Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 50(2):353–363

    Article  PubMed  CAS  Google Scholar 

  27. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA et al (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48(1):35–45

    Article  PubMed  CAS  Google Scholar 

  28. http://www.emea.europa.eu/humandocs/Humans/EPAR/trudexa/trudexa.htm.

  29. http://www.emea.europa.eu/humandocs/Humans/EPAR/humira/humira.htm.

  30. van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL et al (2004) Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 63(5):508–516

    Article  PubMed  Google Scholar 

  31. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS et al (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50(5):1400–1411

    Article  PubMed  CAS  Google Scholar 

  32. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al (2006) The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54(1):26–37

    Article  PubMed  CAS  Google Scholar 

  33. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW et al (2002) Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46(3):614–624

    Article  PubMed  CAS  Google Scholar 

  34. http://www.emea.europa.eu/humandocs/Humans/EPAR/kineret/kineret.htm.

  35. Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ et al (2004) A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 63(9):1062–1068

    Article  PubMed  CAS  Google Scholar 

  36. Fox RI, Herrmann ML, Frangou CG, Wahl GM, Morris RE, Strand V et al (1999) Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 93(3):198–208

    Article  PubMed  CAS  Google Scholar 

  37. Bruynesteyn K, van der Heijde D, Boers M, Saudan A, Peloso P, Paulus H, Houben H, Griffiths B, Edmonds J, Bresnihan B, Boonen A, ven del Linden S (2002) Determination of the minimal clinical important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde, and Larsen/Scott scoring methods by clinical experts and comparison with smallest detectable difference. Arthritis Rheum 46(4):913–920

    Article  PubMed  Google Scholar 

  38. Boers M (2006) Abatacept in rheumatoid arthritis: a new branch on the “biologics” tree. Ann Intern Med 144(12):933–935

    PubMed  CAS  Google Scholar 

  39. Boers M (2005) Use of the American College of Rheumatology N (ACR-N) index of improvement in rheumatoid arthritis: argument in opposition. Arthritis Rheum 52(6):1642–1645

    Article  PubMed  Google Scholar 

  40. Voskuyl AE, Dijkmants BA (2006) Remission and radiographic progression in rheumatoid arthritis. Clin Exp Rheumatol 24[Suppl 43]:37–40

  41. Klippel JH (2000) Biologic therapy for rheumatoid arthritis. N Engl J Med 343(22):1640–1641 [Erratum in: N Engl J Med (2001) 344(1):76]

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors are grateful to J.D. Baggott for editing.

Conflict of interest statement

None of the authors have any financial or personal relationships with other people or organizations that could be considered conflicts of interest for the present work.

Author information

Authors and Affiliations

  1. Laboratory of Regulatory Policies, Mario Negri Institute for Pharmacological Research, Via Eritrea 62, 20157, Milan, Italy

    Vittorio Bertele’, Alessandro Assisi, Valeria Di Muzio, Danila Renzo & Silvio Garattini

Authors
  1. Vittorio Bertele’
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandro Assisi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Valeria Di Muzio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Danila Renzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Silvio Garattini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vittorio Bertele’.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bertele’, V., Assisi, A., Di Muzio, V. et al. New antirheumatic drugs: any real added value? A critical overview of regulatory criteria for their marketing approval. Eur J Clin Pharmacol 63, 879–889 (2007). https://doi.org/10.1007/s00228-007-0338-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-007-0338-9

Keywords

Search

Navigation